Two Sigma Investments
RARE icon

Two Sigma Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Two Sigma Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,000
Closed -$281K – 3246
2016
Q4 		$281K Buy
+4,000
New +$284K ﹤0.01% 2778

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Two Sigma Investments's RARE Position: Q1 2026 in Review

Two Sigma Investments increased its Ultragenyx Pharmaceutical (RARE) stake by 420% in Q1 2026, buying an estimated $40.1M and bringing the position to 2,205,820 shares worth $46.2M. The position accounts for 0.04% of the portfolio, ranked #531.

Two Sigma Investments first reported a position in RARE in Q1 2015 and has held it in 27 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Two Sigma Investments held 2,205,820 shares of Ultragenyx Pharmaceutical worth $46.2M as of Q1 2026.
  • Two Sigma Investments bought 1,781,771 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $40.1M.
  • Ultragenyx Pharmaceutical made up 0.04% of Two Sigma Investments's portfolio in Q1 2026, its #531 holding.
  • Two Sigma Investments first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 27 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.